NASDAQ: YMABY Mabs Therapeutics Inc Stock Ownership - Who owns Y Mabs Therapeutics?
Insider buying vs selling
Have Y Mabs Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Susan Laura Smith | SVP CHIEF COMMERCIAL OFFICER | 2024-03-05 | 1,682 | $16.55 | $27.84kSell |
| Thomas Gad | CHIEF BUSINESS OFFICER | 2024-03-05 | 3,900 | $16.44 | $64.12kSell |
| Vignesh Rajah | SVP CHIEF MEDICAL OFFICER | 2024-03-05 | 1,711 | $16.53 | $28.28kSell |
| Thomas Gad | Chief Business Officer | 2023-12-21 | 50,000 | $2.00 | $100.00kBuy |
| Thomas Gad | Chief Business Officer | 2023-12-15 | 50,000 | $6.61 | $330.50kSell |
| Thomas Gad | Chief Business Officer | 2023-12-14 | 50,000 | $6.83 | $341.50kSell |
| Thomas Gad | Chief Business Officer | 2023-12-13 | 50,000 | $6.58 | $329.00kSell |
| Johan Wedellwedellsborg | Director | 2023-12-11 | 6,455 | $6.85 | $44.23kBuy |
| Biotech Aps Wg | Director | 2023-12-11 | 6,455 | $6.85 | $44.23kBuy |
| Biotech Aps Wg | Director | 2023-12-11 | 102,863 | $7.01 | $720.86kBuy |
YMAB insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when YMAB insiders and whales buy or sell their stock.
YMAB Shareholders
What type of owners hold Y Mabs Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Johan Wedellwedellsborg | 11.94% | 5,225,710 | $75.09M | Insider |
| Biotech Aps Wg | 10.41% | 4,559,233 | $65.52M | Insider |
| Blackrock Inc | 6.66% | 2,917,080 | $41.92M | Institution |
| Thomas Gad | 5.81% | 2,544,444 | $36.56M | Insider |
| Vanguard Group Inc | 5.13% | 2,244,238 | $32.25M | Institution |
| James Healy | 5.08% | 2,222,386 | $31.94M | Insider |
| Sofinnova Investments Inc | 5.01% | 2,194,278 | $31.53M | Institution |
| Polar Capital Holdings PLC | 4.70% | 2,056,872 | $29.56M | Institution |
| Ashu Tyagi | 3.19% | 1,395,070 | $20.05M | Insider |
| D E Shaw Co Inc | 3.02% | 1,323,780 | $19.02M | Institution |
YMAB vs Biotech Stocks
Y Mabs Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.